Novel Anti-Human Transferrin Receptor Antibody Capable of Penetrating Blood-Brain Barrier
US-2019338043-A1 · Nov 7, 2019 · US
Anti-human transferrin receptor antibody permeating blood-brain barrier
US11248045B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11248045-B2 |
| Application number | US-201615739200-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 24, 2016 |
| Priority date | Jun 24, 2015 |
| Publication date | Feb 15, 2022 |
| Grant date | Feb 15, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are a means to convert compounds having physiological or pharmacological activity and unable to pass through the blood-brain barrier into a form that allows them to pass through the blood-brain barrier, and compounds converted thereby. The means is an anti-human transferrin receptor antibody and the converted compounds are molecular conjugates between physiologically active protein or pharmacologically active low-molecular-weight compounds and an anti-human transferrin receptor antibody.
First claim
Opening claim text (preview).
The invention claimed is: 1. A fusion protein which penetrates the blood brain barrier following administration to a human comprising a humanized anti-human transferrin receptor (anti-hTfR) antibody amino acid sequence and a human iduronate 2-sulfatase amino acid sequence, wherein the fusion protein is selected from (1) to (3) below: (1) the fusion protein, wherein the humanized anti-hTfR antibody light chain has the amino acid sequence set forth as SEQ ID NO:164, and wherein the humanized anti-hTfR antibody heavy chain is linked, on the C-terminal side thereof and via a linker sequence Gly-Ser, to the human iduronate 2-sulfatase, and the whole linked heavy chain has the amino acid sequence set forth as SEQ ID NO:247, (2) the fusion protein, wherein the humanized anti-hTfR antibody light chain has the amino acid sequence set forth as SEQ ID NO:180, and wherein the humanized anti-hTfR antibody heavy chain is linked, on the C-terminal side thereof and via a linker sequence Gly-Ser, to the human iduronate 2-sulfatase, and the whole linked heavy chain has the amino acid sequence set forth as SEQ ID NO:249, and (3) the fusion protein, wherein the humanized anti-hTfR antibody light chain has the amino acid sequence set forth as SEQ ID NO:196, and wherein the humanized anti-hTfR antibody heavy chain is linked, on the C-terminal side thereof and via a linker sequence Gly-Ser, to the human iduronate 2-sulfatase, and the whole linked heavy chain has the amino acid sequence set forth as SEQ ID NO:251. 2. A polynucleotide encoding the amino acid sequence of the fusion protein according to claim 1 . 3. An expression vector comprising the polynucleotide according to claim 2 that is incorporated therein. 4. A mammalian cell transformed with the expression vector according to claim 3 . 5. A method for the treatment of Hunter syndrome comprising parenterally administering a therapeutically effective amount of the fusion protein according to claim 1 to a patient with Hunter syndrome. 6. A pharmaceutical agent comprising the fusion protein according to claim 1 .
Assignees
Inventors
Classifications
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
Iduronate-2-sulfatase (3.1.6.13) · CPC title
- A61P25/00Primary
Drugs for disorders of the nervous system · CPC title
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11248045B2 cover?
- Disclosed are a means to convert compounds having physiological or pharmacological activity and unable to pass through the blood-brain barrier into a form that allows them to pass through the blood-brain barrier, and compounds converted thereby. The means is an anti-human transferrin receptor antibody and the converted compounds are molecular conjugates between physiologically active protein or…
- Who is the assignee on this patent?
- Japan Chem Res
- What technology area does this patent fall under?
- Primary CPC classification A61P25/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).